EQUITY ALERT: Rosen Law Firm Reminds Pacira Pharmaceuticals, Inc. Investors of Important December 2, 2014 Deadline in Class Action -- PCRX


NEW YORK, Nov. 21, 2014 (GLOBE NEWSWIRE) -- Rosen Law Firm reminds purchasers of Pacira Pharmaceuticals, Inc. common stock (Nasdaq:PCRX) during the period from April 9, 2012 through September 24, 2014, of the important December 2, 2014 lead plaintiff deadline in the class action.

To join the Pacira class action, visit the firm's website at http://rosenlegal.com/cases-390.html, or call Phillip Kim or Kevin Chan toll-free at 866-767-3653; you may also email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.

Pacira is a specialty pharmaceutical company whose products are used in hospitals and ambulatory surgery centers. One of its products, EXPAREL, has completed Phase III clinical trials for postsurgical analgesia-nerve block administration.

According to the lawsuit, Pacira: (i) overstated EXPAREL's efficacy; (ii) improperly promoted EXPAREL as being able to work for up to 72 hours despite it being only approved for 24-hour pain relief; (iii) improperly claimed EXPAREL as safe and effective for use in cholecystectomy and colectomy, even though its approved labeling does not provide for such use; and (iv) concealed that it derives a substantial portion of its revenue from off label marketing.

On September 25, 2014, Pacira revealed that it had received a Warning Letter from the U.S. Food and Drug Administration concerning the misleading marketing of EXPAREL. On this news, Pacira's share price fell $11.66 per share, or over 10%, to close at $94.62 per share on September 25, 2014.

If you wish to serve as lead plaintiff, you must move the Court no later than December 2, 2014. If you wish to join the litigation and recover your losses go to http://rosenlegal.com/cases-390.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.



            

Contact Data